Shots:
- Abbisko Therapeutics has entered into a strategic research collaboration & license agreement with Eli Lilly to discover & develop novel therapeutics across multiple targets
- Abbisko will leverage its early-stage drug discovery platform, R&D ecosystem, & development expertise to conduct discovery & early-stage development of novel therapeutics against disease targets selected by Lilly
- As per the deal, Abbisko will receive an upfront payment & development, regulatory and commercial milestone payments totaling up to $1.9B, with tiered royalties based on annual net sales of products arising from this collaboration
Ref: PRnewswire | Image: Abbisko & Eli Lilly | Press Release
Related News: Ascidian and Eli Lilly Partner to Advance RNA Exon Editors for Devastating Kidney Diseases in a ~$1.9B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
